HLA‐DRB alleles are differentially expressed by tumor cells in breast carcinoma
- 23 June 2004
- journal article
- clinical trial
- Published by Wiley in International Journal of Cancer
- Vol. 112 (3) , 399-406
- https://doi.org/10.1002/ijc.20441
Abstract
The biologic and prognostic significance of HLA‐DR expression and T‐cell infiltration in breast carcinoma are presently controversial. To test the hypothesis that these factors are influenced by particular HLA‐DRB alleles, 52 breast tumor samples, composed of 26 DRB1*04 and 26 non‐DRB1*04 tumors, were assessed using immunohistochemistry for expression of DR and its associated invariant chain (Ii) and for infiltrating CD3+ T cells. While DR expression by tumor cells was significantly associated with T‐cell infiltration, DRB1*04 tumors were more frequently DR+Ii+ and contained smaller CD3+ infiltrates than non‐DRB1*04 tumors. This difference was largely attributable to DRB1*07 tumors, which were typically DR−Ii−, although they contained similar numbers of T cells to DR+Ii+ tumors. Further analysis of DR+ tumors using allotype discriminating antibodies revealed that DRB1*04 alleles were always expressed, while non‐DRB1*04 alleles were inconsistently expressed. The results of this study provide the first reported evidence that DRB alleles influence DR expression and T‐cell infiltration in breast carcinoma and suggest that multiple factors contribute to DR expression. Ongoing studies aimed at elucidating the molecular and immunologic mechanisms controlling differential DR expression and implications for prognosis and outcome should further our understanding of the antitumor immune response and evasion strategies employed by tumor cells.Keywords
This publication has 35 references indexed in Scilit:
- HLA class I antigen abnormalities and immune escape by malignant cellsSeminars in Cancer Biology, 2002
- HER-2/neu-derived peptide 884–899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clonesCancer Immunology, Immunotherapy, 2002
- The Central Role of CD4+ T Cells in the Antitumor Immune ResponseThe Journal of Experimental Medicine, 1998
- The role of CD4+ T cell responses in antitumor immunityCurrent Opinion in Immunology, 1998
- Class II-Transfected Tumor Cells Directly Present Endogenous Antigen to CD4+ T Cells In Vitro and Are APCs for Tumor-Encoded Antigens In VivoJournal of Immunotherapy, 1998
- DIFFERENT PATTERNS OF HLA‐DR ANTIGEN EXPRESSION IN NORMAL EPITHELIUM, HYPERPLASTIC AND NEOPLASTIC MALIGNANT LESIONS OF THE BREASTInternational Journal of Immunogenetics, 1995
- Effect of gamma interferon on HLA class‐I and ‐II transcription and protein expression in human breast adenocarcinoma cell linesInternational Journal of Cancer, 1990
- Correlation of HLA‐D/Ii antigen expression in breast carcinoma with local lymphohistiocytic infiltration reveals considerable dysregulation in a subset of tumorsInternational Journal of Cancer, 1989
- HLA class II sublocus expression in benign and malignant breast epitheliumThe Journal of Pathology, 1988
- HLA-DR antigens on differentiating human mammary gland epithelium and breast tumoursBritish Journal of Cancer, 1987